BC Week In Review | Aug 31, 2009
Company News

Endocyte, Bristol-Myers deal

Endocyte received an undisclosed milestone payment from Bristol-Myers under a 2005 deal granting the pharma a license to vitamin-targeting technology. The payment was triggered by the start of a Phase II trial for Epofolate ( BMS-753493...
BioCentury | Dec 15, 2008
Strategy

BMS cancer pipeline

BMS cancer pipeline Compound [partner] Target Lead indication Status Erbitux cetuximab [Merck KGaA (Xetra:MRK)/Eli Lilly (NYSE:LLY)] Epidermal growth factor (EGF) receptor 1 (HER1) (ErbB1) Colorectal cancer; squamous cell carcinoma of the head and neck (SCCHN)...
Items per page:
1 - 2 of 2